MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.

TitleMYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.
Publication TypeJournal Article
Year of Publication2022
AuthorsQiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, Gu S, Tang Q, Zhang Y, Syamala S, Seo J-H, Bell C, O'Connor E, Liu Y, Schaeffer EM, R Karnes J, Weinmann S, Davicioni E, Morrissey C, Cejas P, Ellis L, Loda M, Wucherpfennig KW, Pomerantz MM, Spratt DE, Corey E, Freedman ML, X Liu S, Brown M, Long HW, Labbé DP
JournalNat Commun
Volume13
Issue1
Pagination2559
Date Published2022 May 13
ISSN2041-1723
KeywordsCell Line, Tumor, Cell Transformation, Neoplastic, Gene Expression Regulation, Neoplastic, Genes, myc, Humans, Male, Prostate, Prostatic Neoplasms, Proto-Oncogene Proteins c-myc, Receptors, Androgen
Abstract

c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression. Although MYC is overexpressed in both early and metastatic disease and associated with poor survival, its impact on prostate transcriptional reprogramming remains elusive. We demonstrate that MYC overexpression significantly diminishes the androgen receptor (AR) transcriptional program (the set of genes directly targeted by the AR protein) in luminal prostate cells without altering AR expression. Analyses of clinical specimens reveal that concurrent low AR and high MYC transcriptional programs accelerate prostate cancer progression toward a metastatic, castration-resistant disease. Data integration of single-cell transcriptomics together with ChIP-seq uncover an increase in RNA polymerase II (Pol II) promoter-proximal pausing at AR-dependent genes following MYC overexpression without an accompanying deactivation of AR-bound enhancers. Altogether, our findings suggest that MYC overexpression antagonizes the canonical AR transcriptional program and contributes to prostate tumor initiation and progression by disrupting transcriptional pause release at AR-regulated genes.

DOI10.1038/s41467-022-30257-z
Alternate JournalNat Commun
PubMed ID35562350
PubMed Central IDPMC9106722
Grant ListP50 CA097186 / CA / NCI NIH HHS / United States
R01 GM107427 / GM / NIGMS NIH HHS / United States
P01 CA163227 / CA / NCI NIH HHS / United States
R01 CA238039 / CA / NCI NIH HHS / United States
R01 CA251599 / CA / NCI NIH HHS / United States
R01 CA251555 / CA / NCI NIH HHS / United States
R01 CA193910 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700